Mi Yanxia, Li Yunchun, Long Yahong
Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2010 Apr;27(2):389-94.
In order to evaluate the biological activity in vitro and the antitumor effects of 131I-conditionally replicating oncolytic adenovirus KH901 on HepG2 human hepatoma xenografts, the leves of GM-CSF expression were determined by ELISA method. A panel of tumor and normal cells was infected with recombinant adenovirus KH901 at MOI of 10 PPC. The medium was harvested to determine the bioactivity of GM-CSF after 24 hours. Nude mice bearing HepG2 human hepatoma xenografts were given 131-KH901. Antitumor effects were assessed using endpoints of tumor growth delay. The data showed that after 24 hours 131-KH901 replicated hugely in tumor cells and produced significant amount of GM-CSF 183.27 +/- 6.90 pg/ml, while producing very small amount of GM-CSF 20.44 +/- 0.77 pg/ml in normal cells. In the treatment of tumor, 131I-KH901 showed higher restraint rate (71.3%) compared to 131I (22.7%) or KH901 (52.7%). Therefore, 131-KH901 can inhibit the growth of human hepatoma cell in nude mice and it may be a potential drug for treating liver cancer.
为了评估131I条件复制型溶瘤腺病毒KH901在体外的生物学活性及其对人肝癌HepG2裸鼠移植瘤的抗肿瘤作用,采用ELISA法检测GM-CSF的表达水平。用重组腺病毒KH901以10个病毒颗粒/细胞的感染复数感染一组肿瘤细胞和正常细胞。24小时后收集培养基以测定GM-CSF的生物活性。给荷人肝癌HepG2裸鼠移植瘤的裸鼠注射131I-KH901。使用肿瘤生长延迟终点评估抗肿瘤作用。数据显示,24小时后131I-KH901在肿瘤细胞中大量复制,产生大量GM-CSF(183.27±6.90 pg/ml),而在正常细胞中产生极少量GM-CSF(20.44±0.77 pg/ml)。在肿瘤治疗中,131I-KH90与I(22.7%)或KH901(52.7%)相比显示出更高的抑制率(71.3%)。因此,131I-KH901可抑制裸鼠中人肝癌细胞的生长,可能是一种治疗肝癌的潜在药物。